





Cleland, J. G.F. , Halliday, B. P. and Prasad, S. K. (2017) Selecting patients 
with nonischemic dilated cardiomyopathy for ICDs. Journal of the 
American College of Cardiology, 70(10), pp. 1228-1231.  
(doi:10.1016/j.jacc.2017.07.748) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 





















Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
Selecting patients with non-ischemic dilated cardiomyopathy for implantable 
cardioverter defibrillators – myocardial function, fibrosis and what’s attached?   
John G F Cleland MD12 
Brian P Halliday MBChB2 
Sanjay K Prasad MD2 
1) Robertson Centre for Biostatistics & Clinical Trials, University of Glasgow & National 
Heart & Lung Institute, Imperial College, London 
2) CMR Unit and Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, 
National Heart & Lung Institute, Imperial College, London 
Correspondence to:- ` 
Professor JGF Cleland, Robertson Institute of Biostatistics and Clinical Trials Unit, 
University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK; 
john.cleland@glasgow.ac.uk 
Page 2 of 8 
The benefit of implantable cardioverter defibrillators (ICDs) in patients with non-ischemic 
dilated cardiomyopathy (NIDCM) and heart failure with reduced left ventricular ejection 
fraction (LVEF) (HF-REF) has been questioned following the DANISH (Danish Study to 
Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on 
Mortality) trial (1). This landmark study of well-treated patients with NIDCM and 
symptomatic HF-REF found no difference in all-cause mortality between patients who were 
randomised to receive an ICD compared to those who were not. Notably, as well as high 
prescription rates of neuro-hormonal pharmacological therapy, 93% of patients with left 
bundle branch block and QRS duration of 150ms or greater received a cardiac 
resynchronisation (CRT) device (1).  CRT pacemakers (CRT-P) reduce sudden cardiac death 
(SCD) which may because CRT improves cardiac function, reduces neurohormonal 
activation and prevents bradycardia-induced fatal arrhythmias (2).  A frequently asked 
question, especially considering the high-rate of super-response to CRT in patients with 
NIDCM, is whether CRT defibrillators (CRT-D) provide incremental benefit to CRT-P in 
this setting. 
Observational studies have failed to demonstrate an additional benefit with CRT-D over 
CRT-P in NIDCM (3,4). In a propensity score analysis of over 5000 patients, Barra and 
colleagues found no difference in mortality when comparing NIDCM patients with CRT-D 
and those with CRT-P (hazard ratio: 0.92; 95% CI 0.73:1.16; p=0.49)(4). In the same analysis 
patients with ischemic cardiomyopathy had better survival with CRT-D compared to CRT-P 
(HR 0.76; 95% CI: 0.62:0.92; p=0.005). However, in a sub-group analysis of the 
COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) 
trial patients with NIDCM randomised to CRT-D had a nominally significant reduction in 
mortality compared to optimal pharmacological therapy (HR 0.50; 95% CI 0.29-0.88; 
p=0.015) while those randomised to CRT-P did not (HR 0.91; 95% CI 0.55-1.49;p=0.70) (5), 
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although there were fewer than 130 patients with NIDCM in the control group of this study.  
Compared to optimal pharmacological therapy, the benefits of CRT-D (HR 0.73; CI 0.52 to 
1.04; P=0.082) and CRT-P (HR 0.72; CI 0.51 to 1.01; P=0.058) were similar. 
In this issue of the Journal, Leyva and colleagues provide further clarification on the issue by 
stratifying patients on the basis of the presence or absence of mid-wall late gadolinium 
enhancement (LGE) on cardiovascular magnetic resonance (CMR) prior to CRT implantation 
(6). Mid-wall LGE occurs in around 1/3 of patients with NIDCM and represents areas of 
replacement fibrosis, which are thought to act as substrate for re-entrant ventricular 
tachycardia (7). In keeping with this, mid-wall LGE predicts a 5-9 fold increased risk of SCD 
and malignant ventricular arrhythmias in patients with NIDCM over the following 5 years 
(7,8). LGE-CMR therefore offers the potential to identify patients at high risk of malignant 
ventricular arrhythmias who may gain benefit from ICD therapy in addition to CRT-P (9).  
Leyva and colleagues studied 252 patients with NIDCM and HF-REF who underwent LGE-
CMR prior to CRT between 2002 and 2017 (6). Multivariable proportional hazard modelling 
was used to compare all-cause mortality for patients with CRT-D or CRT-P, stratified by the 
presence or absence of mid-wall fibrosis. The baseline characteristics of the study population 
were similar to previous CRT trials (2,5). The average age of patients was 66 years, 61% 
were men and the majority reported moderate-to-severe heart failure symptoms (83% with 
New York Heart Association Class III-IV symptoms) at baseline. Importantly, however, only 
65% were prescribed beta-blockers and 47% mineralocorticoid receptor antagonists at 
baseline; subsequent pharmacological treatment was not reported. Consistent with the 
baseline characteristics, which suggested a population with advanced disease, the mortality 
rate during follow-up was high: patients with mid-wall fibrosis had an annual mortality rate 
of 12.8% compared to 6.9% in those without fibrosis. As expected, on multivariable analysis, 
the presence of mid-wall fibrosis predicted higher mortality (HR 2.31; 95% CI: 1.45:3.68; 
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p<0.001). Following adjustment for the presence of fibrosis, age, NYHA class, hypertension 
and atrial fibrillation, CRT-D was associated with lower all-cause mortality compared to 
CRT-P (HR: 0.33; 95% CI: 0.14-0.77; p=0.01).  However, when the population was divided 
based on the presence or absence of mid-wall fibrosis, only those patients with mid-wall 
fibrosis appeared to gain mortality benefit with CRT-D (HR: 0.23; 95% CI 0.07-0.75). 
The findings should be interpreted within the context of an observational study where it is 
impossible to control for all factors influencing the choice of device at baseline. The reported 
prescription of pharmacological agents proven to reduce the risk of SCD (10) was also sub-
optimal. Nevertheless, the study supports a novel solution to a major challenge encountered 
within daily practice, highlighting the potential utility of LGE-CMR in identifying patients 
most likely to benefit ICD therapy in addition to CRT-P.  Whether the benefit of ICD therapy 
is influenced by the proximity of the LGE to the left ventricular lead is also an interesting 
area for future research. Pacing close to areas of replacement fibrosis could be pro-arrhythmic 
(11). 
The DANISH study has reinforced the urgent need to move beyond left ventricular ejection 
fraction (LVEF) for the selection of patients with NIDCM for ICD therapy (1).  It does not 
come as a surprise that a single measurement of LVEF does not adequately identify those 
patients with NIDCM who will benefit from ICDs. NIDCM is a heterogeneous disease 
affecting a diverse range of patients with a wide range of response to pharmacological 
therapies. The underlying aetiology is varied with multiple different triggers and a large 
number of gene-variants encoding a wide range of proteins labelled as pathogenic (12).  
Reduced ventricular function is only one of the many contributing factors involved in the 
generation of potentially fatal ventricular arrhythmias. It appears likely that ventricular 
arrhythmia is the result of many different processes interacting to form a ‘perfect storm’. 
Structural substrate such as replacement fibrosis, autonomic dysfunction, electrical instability 
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and genetic susceptibility all confer adverse risk.  Other methods of identifying increased 
arrhythmic risk include microvolt T wave alternans and QRS fragmentation as measures of 
electrical instability and the detection of high-risk genetic variants such as Lamin A/C in the 
risk stratification of patients with NIDCM (13). 
As LVEF falls and heart failure progresses, the risk of non-sudden death rises even more 
rapidly than the risk of SCD, resulting in the selection of many patients for ICD therapy 
based on current guidelines who succumb to non-sudden causes of death rather than sudden 
causes (Figure 1) (14).  One, perhaps surprising aspect of the data from Leyva and colleagues 
is the apparent benefit of ICD therapy in a sub-group of patients with relatively advanced HF 
and an average age of 66 years. Sub-group analysis of the DANISH study, shows no benefit 
from ICD therapy in patients aged >59 years or in those with a NT-pro-BNP>1177pg/ml (1). 
This highlights the need for a model which accurately balances the risk of death from non-
sudden causes against the risk of SCD to select those patients most likely to benefit from 
successful ICD therapies (Figure 1). It is likely that the incorporation of multiple variables in 
addition to LVEF will be required to accomplish such a goal. 
One further concept that must be kept in mind is time! Landmark studies of ICDs suggest that 
they reduce mortality, in absolute terms, by about 1-2% annually. Patients with a higher 
overall risk obtain less benefit from an ICD either because they die from causes other than an 
arrhythmia or because the arrhythmia they die from heralds advanced disease from which 
they are soon to die. Patients must be exposed to a long period of risk in order to justify the 
implantation of an ICD, both in clinical and economic terms. Younger patients with few co-
morbid conditions may be at a low annual risk of events but, if they avoid SCD, they might 
survive another 30 years. Their cumulative risk will be high. Of course, the duration of risk 
might not just be dictated by factors that shorten life-expectancy but also by treatments that 
correct the underlying problem and reduce the arrhythmic risk (15). Currently, the evidence 
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of a substantial benefit from ICDs is strong only for younger patients with no co-morbidities 
and ‘mild’ heart failure but a very low left ventricular ejection fraction, a rather select group.     
In conclusion, these new data reinforce the potential utility of LGE-CMR in the selection of 
patients with NIDCM who may benefit from ICD therapy. In order to change current 
guidelines, randomised trials are needed to confirm the benefit of interventions, including 
ICD therapy, in patients on optimal pharmacological therapy with mid-wall fibrosis and/or 
additional features which confer a high-risk of SCD. CMR-Guide (NCT01918215) is 
currently underway with the aim of adding much-needed randomised evidence to the 
observational data currently available.  Important additional questions for future research 
include whether it is possible to prevent the development of arrhythmic substrate, such as 
replacement fibrosis, through early disease detection and treatment and whether it is 
potentially reversible with the use of novel therapies such as anti-fibrotic agents.  
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Figure 1. Selecting patients for implantable cardioverter defibrillators 
Factors to consider during the selection of patients with non-ischemic cardiomyopathy for 
implantable cardioverter defibrillators for the primary prevention of sudden cardiac death. 
 
 
 
 

